首页> 外文期刊>Frontiers in Physiology >Cardioprotective Effects of QiShenYiQi Dripping Pills on Transverse Aortic Constriction-Induced Heart Failure in Mice
【24h】

Cardioprotective Effects of QiShenYiQi Dripping Pills on Transverse Aortic Constriction-Induced Heart Failure in Mice

机译:芪参益气滴丸对小鼠主动脉缩窄性心力衰竭的心脏保护作用

获取原文
       

摘要

QiShenYiQi dripping pills (QSYQ), a traditional Chinese medicine, are commonly used to treat coronary heart disease, and QSYQ was recently approved as a complementary treatment for ischemic heart failure in China. However, only few studies reported on whether QSYQ exerts a protective effect on heart failure induced by pressure overload. In this study, we explored the role of QSYQ in a mouse model of heart failure induced by transverse aortic constriction (TAC). Twenty-eight C57BL/6J mice were divided into four groups: Sham + NS group, Sham + QSYQ group, TAC + NS group, and TAC + QSYQ group. QSYQ dissolved in normal saline (NS) was administered intragastrically (3.5 mg/100 g/day) in the Sham + QSYQ and TAC + QSYQ groups. In the Sham + NS and TAC + NS groups, NS was provided every day intragastrically. Eight weeks after TAC, echocardiography, and cardiac catheterization were performed to evaluate the cardiac function, and immunofluorescent staining with anti-actinin2 antibody was performed to determine the structure of the myocardial fibers. Moreover, TUNEL staining and Masson trichrome staining were employed to assess the effects of QSYQ on cardiac apoptosis and cardiac fibrosis. Western blots and real-time polymerase chain reaction (PCR) were used to measure the expression levels of vascular endothelial growth factor (VEGF) in the heart, and immunohistochemical staining with anti-CD31 antibody was performed to explore the role of QSYQ in cardiac angiogenesis. Results showed that TAC-induced cardiac dysfunction and disrupted structure of myocardial fibers significantly improved after QSYQ treatment. Moreover, QSYQ treatment also significantly improved cardiac apoptosis and cardiac fibrosis in TAC-induced heart failure, which was accompanied by an increase in VEGF expression levels and maintenance of microvessel density in the heart. In conclusion, QSYQ exerts a protective effect on TAC-induced heart failure, which could be attributed to enhanced cardiac angiogenesis, which is closely related to QSYQ. Thus, QSYQ may be a promising traditional Chinese medicine for the treatment of heart failure induced by pressure overload such as hypertension.
机译:七神益气滴丸(QSYQ)是一种中药,通常用于治疗冠心病,最近,QSYQ被批准为中国缺血性心力衰竭的补充疗法。但是,只有很少的研究报道QSYQ是否对压力超负荷引起的心力衰竭具有保护作用。在这项研究中,我们探讨了QSYQ在由横向主动脉缩窄(TAC)诱发的心力衰竭小鼠模型中的作用。将28只C57BL / 6J小鼠分为四组:Sham + NS组,Sham + QSYQ组,TAC + NS组和TAC + QSYQ组。 Sham + QSYQ和TAC + QSYQ组的胃内注射(3.5 mg / 100 g /天)溶解于生理盐水(NS)中的QSYQ。在Sham + NS和TAC + NS组中,每天在胃内提供NS。 TAC后八周,进行超声心动图检查和心脏导管检查以评估心脏功能,并用抗actinin2抗体进行免疫荧光染色以确定心肌纤维的结构。此外,TUNEL染色和Masson三色染色被用于评估QSYQ对心脏细胞凋亡和心脏纤维化的影响。使用Western印迹和实时聚合酶链反应(PCR)检测心脏中血管内皮生长因子(VEGF)的表达水平,并用抗CD31抗体进行免疫组织化学染色以探讨QSYQ在心脏血管生成中的作用。结果显示,经QSYQ治疗后,TAC引起的心脏功能障碍和心肌纤维结构破坏明显改善。此外,QSYQ治疗还显着改善了TAC诱发的心力衰竭中的心脏凋亡和心脏纤维化,并伴有VEGF表达水平的增加和心脏微血管密度的维持。总之,QSYQ对TAC诱发的心力衰竭具有保护作用,这可能归因于增强的心脏血管生成,这与QSYQ密切相关。因此,QSYQ可能是一种有前景的中药,可用于治疗由压力超负荷(如高血压)引起的心力衰竭。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号